主页 > 医学讨论 >
Dharmacon - Bayer Expand SiRNA Supply Agreement
"We are pleased that Bayer, a leading global pharmaceutical firm, chose to expand its use of Dharmacon's reagents after gaining first-hand experience with siRNA reagents designed using our SMARTselection and SMARTpool technologies," said Rosalie T. Duong, executive vice president of sales and marketing at Dharmacon. "This expansion of our agreement with Bayer provides further performance and reliability validation of our SMART technologies in high throughput drug discovery research."
Under the terms of the agreement, during the first quarter of 2004 Dharmacon will supply Bayer with siRNA reagents for approximately 4,000 gene targets for research in several therapeutic areas. The SMARTpool siRNA supplied by Dharmacon will be a major gene-silencing platform used for Bayer's in-house target validation work.
"The reliable silencing seen with Dharmacon's SMARTpool siRNA reagents in our initial evaluation gave us the confidence to significantly expand our relationship with Dharmacon," said Haren Vasavada, Ph.D., Director of Molecular Biology at the Bayer Research Center in West Haven, Connecticut. "This new agreement reflects Bayer's ongoing commitment to leadership in applying valuable new technologies like RNAi to our drug discovery research."
RNAi, used for drug target identification and validation, employs siRNA sequences to silence the expression of specific genes targeted for study. Dharmacon's proprietary technologies create potent and specific gene silencing agents that can accelerate critical investigations across a broad range of biomedical and biological research. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-27 17:11
医学,生命科学网